Breast Cancer Coverage from Every Angle

Does Extended Adjuvant Capecitabine Improve Survival in Triple-Negative Breast Cancer?

By: Kayci Reyer
Posted: Tuesday, April 21, 2020

According to research published in the Journal of Clinical Oncology, extended adjuvant capecitabine does not result in survival benefits in patients with early triple-negative breast cancer who have undergone standard chemotherapy. However, according to Miguel Martín, MD, PhD, of the Spanish Breast Cancer Group in Madrid, and colleagues, a preplanned subset analysis revealed that patients with the nonbasal phenotype seemed to reap some benefit from capecitabine, but further validation of this finding is necessary.

Known as GEICAM-CIBOMA, the phase III study included 876 patients who were randomly assigned to receive either capecitabine (n = 448) or undergo observation (n = 428). At a median follow-up of 7.3 years, disease-free survival was comparable in both groups (hazard ratio = 0.82; 95% confidence interval, 0.63–1.06; P = .136). However, patients with nonbasal phenotypes did seem to experience some survival benefit when compared with those with basal phenotypes. The addition of capecitabine resulted in a disease-free survival hazard ratio of 0.53 versus 0.94 (P= .0694) and an overall survival hazard ratio of 0.42 versus 1.23 (P = .0052) in nonbasal versus basal subgroups, respectively. Overall, 75.2% of patients underwent all eight cycles of treatment, in line with tolerability expectations.

Patients eligible for this study had operable triple-negative breast cancer and had previously received chemotherapy containing anthracycline, taxane, or both. Participants were required to have node-positive disease unless they had node-negative disease with a tumor of at least 1 cm. The majority of patients had a basal phenotype (73.9%), underwent prior combination anthracycline/taxane treatment (67.5%), and/or had node-negative disease (55.9%). The median patient age was 49 years.

Disclosure: For full disclosures of the study authors, please visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.